MedicaidApril 3, 2025
Clinical Criteria updates
Effective May 7, 2025
Summary: The Pharmacy and Therapeutics (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem. These policies were developed, revised, or reviewed to support clinical coding edits.
Visit Clinical Criteria to search for specific policies. For questions or additional information, use this email.
Please see the explanation/definition for each category of Clinical Criteria below:
- New: newly published criteria
- Revised: addition or removal of medical necessity requirements; new document number
Please share this notice with other members of your practice and office staff.
Please note:
- The Clinical Criteria listed below apply only to the medical drug benefits contained within the member’s medical plan. This does not apply to pharmacy services.
- This notice is meant to inform the provider of new or revised criteria that have been adopted by the health plan only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.
Effective Date | Clinical Criteria Number | Clinical Criteria Title | Status |
May 7, 2025 | CC-0274 | Bizengri (zenocutuzumab-zbco) | New |
May 7, 2025 | CC-0275 | Ziihera (zanidatamab-hrii) | New |
May 7, 2025 | CC-0276 | Tryngolza (olezarsen) | New |
May 7, 2025 | CC-0072 | Vascular Endothelial Growth Factor (VEGF) Inhibitors | Revised |
May 7, 2025 | CC-0185 | Oxlumo (lumasiran) | Revised |
May 7, 2025 | CC-0198 | Relizorb (immobilized lipase) cartridge | Revised |
May 7, 2025 | CC-0256 | Rivfloza (nedosiran) | Revised |
May 7, 2025 | CC-0042 | Monoclonal Antibodies to Interleukin-17 | Revised |
May 7, 2025 | CC-0063 | Ustekinumab Agents (Stelara, Selarsdi, Imuldosa, Pyzchiva, Otulfi, Wezlana, Yesintek) | Revised |
May 7, 2025 | CC-0058 | Bynfezia Pen, Sandostatin, or Sandostatin LAR (Octreotide) / Octreotide Agents | Revised |
May 7, 2025 | CC-0130 | Imfinzi (durvalumab) | Revised |
May 7, 2025 | CC-0094 | Pemetrexed | Revised |
May 7, 2025 | CC-0078 | Orencia (abatacept) | Revised |
Anthem Blue Cross and Blue Shield Healthcare Solutions is the trade name of Community Care Health Plan of Nevada, Inc. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.
NVBCBS-CD-079049-25-CPN78054
To view this article online:
Visit https://providernews.anthem.com/nevada/articles/clinical-criteria-updates-24752
Or scan this QR code with your phone